What is the Current Share Price of Morepen Laboratories Ltd?
- Answer Field
-
Morepen Laboratories Ltd share price is for NSE ₹ 53.16 & for BSE ₹ 53.14 as on Jun 25 2026 03:30 PM.
Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply
MOREPEN LAB. LTD is currently trading at ₹53.16, up by ₹1.04 from the previous close. The stock touched an intraday high of ₹54.20 and a low of ₹51.60 during the latest trading session. Over the past one year, MOREPEN LAB. LTD has delivered a loss of 15.47%, while the stock has gained 21.59% in the last one month.
| Particulars | MAR 2026 (Values in Cr) |
|---|---|
| Revenue | 462.81 |
| Operating Expense | 444.00 |
| Net Profit | 20.12 |
| Net Profit Margin (%) | 4.34 |
| Earnings Per Share (EPS) | 0.37 |
| EBITDA | 32.13 |
| Effective Tax Rate (%) | 27.14 |
| Company Name | Price | P/E | P/B | Market Cap | 52 Week Low | 52 Week High |
|---|---|---|---|---|---|---|
| AMBALAL SARABHAI ENT L | 31.51 | 13.02 | 1.52 | 241.47 | 23.12 | 38.85 |
| BLISS GVS PHARMA LTD | 492.50 | 39.98 | 4.37 | 5223.27 | 118.35 | 495.00 |
| CIPLA LTD. | 1440.30 | 30.57 | 3.37 | 116353.96 | 1165.55 | 1672.20 |
| FERMENTA BIOTECH LTD. | 365.50 | 16.12 | 2.64 | 1075.70 | 256.40 | 399.00 |
| Company Name | Price | P/E | P/B | Market Cap | 52 Week Low | 52 Week High |
|---|---|---|---|---|---|---|
| AMBALAL SARABHAI ENT L | 31.51 | 22.03 | 4.05 | 241.47 | 23.12 | 38.85 |
| AMRUTANJAN HEALTH CARE LTD. | 538.05 | 24.12 | 4.20 | 1555.54 | 490.00 | 789.95 |
| ASTRAZENECA PHARMA INDIA LTD. | 8382.65 | 109.48 | 24.01 | 20956.63 | 7630.00 | 9850.00 |
| BLISS GVS PHARMA LTD | 492.50 | 53.13 | 4.52 | 5223.27 | 118.35 | 495.00 |
In the second quarter of fiscal year 2024-25, Morepen Laboratories Limited reported a consolidated net profit of ₹21.26 crore, marking a 45% increase from ₹14.63 crore in the previous quarter. Revenue from operations rose by 5.2% quarter-on-quarter to ₹421.77 crore. The company's EBITDA margin improved to 12.25%, reflecting enhanced operational efficiency. These robust financial results have positively influenced the Morepen Lab share price, reflecting increased investor confidence.
The 2023-24 annual report of Morepen Laboratories Limited provides comprehensive insights into its financial performance and strategic initiatives. The company achieved a total income of ₹1,744.6 crore, registering a growth of 7.7% from the previous year. The report highlights Morepen's focus on expanding its product portfolio, enhancing operational efficiency, and implementing cost optimisation measures. These efforts have contributed to a stable Morepen Laboratories share price by showcasing the company's commitment to growth and profitability.
For the fiscal year 2023-24, Morepen Laboratories Limited declared a total dividend of ₹1.50 per share, reflecting its commitment to returning value to shareholders. This consistent dividend payout, supported by strong financial performance, has positively impacted the Morepen Lab share price by enhancing investor confidence.
1. Who is the CEO of Morepen Lab Ltd?
As of November 2024, the Chairman and Managing Director of Morepen Laboratories Limited is Mr. Sushil Suri. He oversees the company's operations and strategic initiatives, influencing the Morepen Lab share price through effective leadership and business expansion.
2. When was Morepen Lab Ltd established?
Morepen Laboratories Limited was established in 1984. Over the decades, it has grown into one of India's leading pharmaceutical companies, impacting the Morepen Laboratories share price through its extensive operations and market presence.
3. What factors influence Morepen Lab Ltd share price fluctuations?
The Morepen Lab share price is influenced by various factors, including the company's financial performance, product launches, regulatory developments, and broader economic conditions. Additionally, market demand for pharmaceutical products, competition, and research and development outcomes play significant roles in determining share price movements.
4. Is Morepen Lab debt free?
No, Morepen Laboratories Limited is not entirely debt-free. The company utilises debt financing to fund its capital-intensive projects and expansion plans. However, it maintains a balanced debt-to-equity ratio, ensuring financial stability and the ability to meet its obligations without adversely affecting the Morepen Laboratories share price.
5. What is the CAGR of Morepen Lab share?
Over the past five years, the Compound Annual Growth Rate (CAGR) of Morepen Lab shares has been approximately 15%. This indicates a steady growth in the Morepen Lab share price, reflecting the company's consistent financial performance and strategic initiatives.
6. How has the Morepen Lab share price performed over the past year?
Over the past year, the Morepen Lab share price has experienced fluctuations influenced by market conditions and company performance. As of November 2024, the share price has shown a modest increase compared to the same period last year, reflecting investor confidence in the company's strategic direction and financial health.
Sign-in to trade with your demat account, or set up a new demat account for free
Morepen Laboratories Ltd share price is for NSE ₹ 53.16 & for BSE ₹ 53.14 as on Jun 25 2026 03:30 PM.
The market cap of Morepen Laboratories Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Jun 25 2026 03:30 PM.
The 52 Week High and Low of Morepen Laboratories Ltd for NSE is ₹ 66.40 and ₹ 33.05 and for BSE is ₹ 66.36 and ₹ 33.44.
The 1 year returns on the stock has been -15.47%.
As on Jun 25 2026 03:30 PM the price-to-earnings (PE) ratio for Morepen Laboratories Ltd share is 43.92.
As on Jun 25 2026 03:30 PM, the price-to-book (PB) ratio for Morepen Laboratories Ltd share is 22.68.
You can trade in Morepen Laboratories Ltd shares with Bajaj Broking by opening a demat account.
To buy Morepen Laboratories Ltd shares on the Bajaj Broking app, follow these steps:
• Login to the Bajaj Broking App
• Click on the Search Icon
• Search “Morepen Laboratories Ltd”
• Click on the BUY icon
• Place a buy order specifying the desired quantity of shares.
• Click BUY again to complete the purchase
No results found